17 nov: Aktier/åbning: Lundbeck og Rockwool i fokus i rødt marked
17 nov: Rockwool leverede lavere omsætning men bedre resultat end ventet
17-11-2016 09:26:42

Zealand increases its share capital as a consequence of exercise of employee warrants

Relateret indhold
09 aug - 
KORR: Zealand Pharma er nu dobbeltnoteret i Danmark og ..
09 aug - 
Zealand Pharma er nu dobbeltnoteret i Danmark og USA
09 aug - 
Zealand vil rejse en halv milliard ved børsnotering i U..
Relateret debat
11:55 - 
Du er undskyldt, der er jo flere skribenter, der det si..
11:15 - 
Jeg kan oplyse at provenuet for en voucher kørt under F..
11:10 - 
Det kan du vel selv slå op , det siger ligesom sig selv..

Company announcement - No. 45 / 2016

Zealand increases its share capital as a consequence of exercise of employee warrants

Copenhagen, 17 November 2016 - Zealand Pharma ("Zealand") has increased its share capital with nominal DKK 8,200 divided into 8,200 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand's employee warrant programs.

Employee warrant programs are part of Zealand's incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand share at a pre-specified price, the exercise price, in specific pre-defined time periods before expiration. For further description of Zealand's warrant programs, see the company's Articles of Association, which are available on the homepage: www.zealandpharma.com.

The exercise price is DKK 77 per share and the total proceeds to Zealand from the capital increase amounts to DKK 631,400.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand's general meetings. Zealand only has one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 26,070,453 divided into 26,070,453 shares with a nominal value of DKK 1 each.

The amendment of Zealand's Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority.

*****

For further information, please contact:

Mats Blom,

Senior Vice President, Chief Financial Officer

Tel: +45 31 53 79 73, email:mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn and a pipeline of proprietary product candidates, which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analog for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as AdlyxinTM in the United States. Lixisenatide has been developed in a fixed-ratio combination with Lantus® (insulin glargine) which product is under regulatory review in the United States and in Europe. 

Zealand's proprietary pipeline includes: Dasiglucagon* (ZP4207) as single-dose rescue treatment for acute, severe hypoglycemia (Phase II); Glepaglutide* (ZP1848) for treatment of short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN)

45-16_1117 Warrant exercise and capital increase


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 771002.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 aug
ZEAL
Jeg mener kun jeg har set at de har ansøgt men nu ser det ud til at de har fået svar.   Zealand Phar..
11
14 aug
ZEAL
Tænk Hvad i 2 ikke kunne udrette hvis i blot brugte jeres tid på noget fornuftigt?
8
16 aug
ZEAL
Du kan omvendt argumentere at der er har været en "rabat" på at der var en frygt knyttet til at man ..
3
14 aug
ZEAL
Det hedder stadig ikek en IPO, for det hedder det kun foerste gang et firma gaar paa boersen....... ..
3
14 aug
ZEAL
Company announcement - No. 35/2017     Zealand Pharma A/S has today registered a capital increase o..
3
12 aug
ZEAL
At Soliqus er markedsleder med kombinationsproduktet Soliqua kan ingen vist betvivle.    Zealand Pha..
3
12 aug
ZEAL
Soliqua er stadig markedsleder med kombinationsprodukterne fra Novo og Sanofi selvom godkendelsen af..
3
00:43
ZEAL
Hvis ....................................................... men jeg sagde jo netop at kroppen bruge..
2
17 aug
ZEAL
Godt set at Zealand Pharma har mulighed for at opnå en FDA voucher som den som Sanofi brugte på Soli..
2
17 aug
ZEAL
Alpehue - Disse FDA programmer er jo netop lavet fordi det ikke er lige så attrativt at udvikle denn..
2

Aktier/åbning: Novo tager bundplacering i rødt marked

18-08-2017 09:18:37
Det danske C20 Cap-indeks fortsætter de negative tendenser fra USA og Asien og åbner med et fald på 0,6 pct. i et overvejende rødt marked, hvor særligt Novo Nordisk skiller sig negativt ud.Eliteindekset følger altså uroen fra de tre store amerikanske aktieindeks, Dow Jones, S&P 500 og Nasdaq, som torsdag dykkede markant for anden gang på tre dage, samt de asiatiske markeder, der ligeledes overveje..

Aktier/tendens: Fald i vente efter terror og Trump-tvivl

18-08-2017 08:17:03
På en fredag med få regnskaber lugter det af fald på det danske aktiemarked, efter de amerikanske børser torsdag løb ind i en større nedtur, som fredag også viser sig i Asien.De tre store amerikanske aktieindeks, Dow Jones, S&P 500 og Nasdaq, dykkede torsdag markant for anden gang på blot tre dage og endte med fald i intervallet 1,2-1,9 pct. efter tvivl om Donald Trumps evne til at gennemføre de l..

MT Højgaard leverer fremgang trods omkostninger til offshoresag

17-08-2017 15:39:35
Entreprenørselskabet MT Højgaard, der ejes 46 pct. af børsnoterede Monberg & Thorsen og 54 pct. af Højgaard Holding, leverede fremgang i andet kvartal trods særlige omkostninger til en tabt sag om vindmøllefundamenter, som koncernen tidligere har oplyst om.Omsætningen steg til 1931 mio. kr. fra 1605 mio. kr. i samme kvartal året før, mens EBIT før særlige poster landede på 63 mio. mod minus 5 mio...

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Fald i vente efter terror og Trump-tvivl
2
Torsdagens aktier: GN trak stikket hjem - ISS og Vestas helt i bund
3
Aktier/åbning: Novo tager bundplacering i rødt marked
4
ECB-medlemmer bekymret: Eurostyrkelse kan stikke af
5
Efter våd sommer: Nu er højsæsonen for dårlige afkast over os

Relaterede aktiekurser

Zealand Pharma A/S 115,00 0,9% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. august 2017 12:51:06
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170808.1 - EUROWEB6 - 2017-08-18 12:51:06 - 2017-08-18 12:51:06 - 1 - Website: OKAY